<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ehf214713" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ESC Heart Fail</journal-id><journal-id journal-id-type="iso-abbrev">ESC Heart Fail</journal-id><journal-id journal-id-type="pmc-domain-id">3356</journal-id><journal-id journal-id-type="pmc-domain">escheart</journal-id><journal-id journal-id-type="publisher-id">EHF2</journal-id><journal-title-group><journal-title>ESC Heart Failure</journal-title></journal-title-group><issn pub-type="epub">2055-5822</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11098647</article-id><article-id pub-id-type="pmcid-ver">PMC11098647.1</article-id><article-id pub-id-type="pmcaid">11098647</article-id><article-id pub-id-type="pmcaiid">11098647</article-id><article-id pub-id-type="pmid">38454651</article-id><article-id pub-id-type="doi">10.1002/ehf2.14713</article-id><article-id pub-id-type="publisher-id">EHF214713</article-id><article-id pub-id-type="other">ESCHF-23-00722</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Effects of pharmacological interventions on mortality in patients with Takotsubo syndrome: a report from the SWEDEHEART registry</article-title><alt-title alt-title-type="right-running-head">Effects of pharmacological interventions on short&#8208; and long&#8208;term mortality in patients with Takotsubo syndrome: a report from the SWEDEHEART registry</alt-title><alt-title alt-title-type="left-running-head">P. Petursson <italic toggle="yes">et al</italic>.</alt-title></title-group><contrib-group><contrib id="ehf214713-cr-0001" contrib-type="author"><name name-style="western"><surname>Petursson</surname><given-names initials="P">Petur</given-names></name><xref rid="ehf214713-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ehf214713-cr-0002" contrib-type="author"><name name-style="western"><surname>O&#353;tarija&#353;</surname><given-names initials="E">Eduard</given-names></name><xref rid="ehf214713-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ehf214713-cr-0003" contrib-type="author"><name name-style="western"><surname>Redfors</surname><given-names initials="B">Bj&#246;rn</given-names></name><xref rid="ehf214713-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ehf214713-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ehf214713-cr-0004" contrib-type="author"><name name-style="western"><surname>R&#229;munddal</surname><given-names initials="T">Truls</given-names></name><xref rid="ehf214713-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ehf214713-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ehf214713-cr-0005" contrib-type="author"><name name-style="western"><surname>Anger&#229;s</surname><given-names initials="O">Oskar</given-names></name><xref rid="ehf214713-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ehf214713-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ehf214713-cr-0006" contrib-type="author"><name name-style="western"><surname>V&#246;lz</surname><given-names initials="S">Sebastian</given-names></name><xref rid="ehf214713-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ehf214713-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ehf214713-cr-0007" contrib-type="author"><name name-style="western"><surname>Rawshani</surname><given-names initials="A">Araz</given-names></name><xref rid="ehf214713-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ehf214713-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ehf214713-cr-0008" contrib-type="author"><name name-style="western"><surname>Hambraeus</surname><given-names initials="K">Kristina</given-names></name><xref rid="ehf214713-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="ehf214713-cr-0009" contrib-type="author"><name name-style="western"><surname>Koul</surname><given-names initials="S">Sasha</given-names></name><xref rid="ehf214713-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="ehf214713-cr-0010" contrib-type="author"><name name-style="western"><surname>Alfredsson</surname><given-names initials="J">Joakim</given-names></name><xref rid="ehf214713-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="ehf214713-cr-0011" contrib-type="author"><name name-style="western"><surname>Hagstr&#246;m</surname><given-names initials="H">Henrik</given-names></name><xref rid="ehf214713-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="ehf214713-cr-0012" contrib-type="author"><name name-style="western"><surname>Loghman</surname><given-names initials="H">Henareh</given-names></name><xref rid="ehf214713-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="ehf214713-cr-0013" contrib-type="author"><name name-style="western"><surname>Hofmann</surname><given-names initials="R">Robin</given-names></name><xref rid="ehf214713-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="ehf214713-cr-0014" contrib-type="author"><name name-style="western"><surname>Fr&#246;bert</surname><given-names initials="O">Ole</given-names></name><xref rid="ehf214713-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="ehf214713-cr-0015" contrib-type="author"><name name-style="western"><surname>Jernberg</surname><given-names initials="T">Tomas</given-names></name><xref rid="ehf214713-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="ehf214713-cr-0016" contrib-type="author"><name name-style="western"><surname>James</surname><given-names initials="S">Stefan</given-names></name><xref rid="ehf214713-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="ehf214713-cr-0017" contrib-type="author"><name name-style="western"><surname>Erlinge</surname><given-names initials="D">David</given-names></name><xref rid="ehf214713-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="ehf214713-cr-0018" contrib-type="author" corresp="yes"><name name-style="western"><surname>Omerovic</surname><given-names initials="E">Elmir</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3875-8621</contrib-id><xref rid="ehf214713-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ehf214713-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>elmir@wlab.gu.se</email></address></contrib></contrib-group><aff id="ehf214713-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>Sahlgrenska University Hospital</institution>
<city>Gothenburg</city>
<country country="SE">Sweden</country>
</aff><aff id="ehf214713-aff-0002" content-type="private-address">
<label>
<sup>2</sup>
</label>
<institution>University of P&#233;cs Medical School</institution>
<city>P&#233;cs</city>
<country country="HU">Hungary</country>
</aff><aff id="ehf214713-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Molecular and Clinical Medicine</named-content>
<institution>Sahlgrenska Academy at University of Gothenburg</institution>
<city>Gothenburg</city>
<country country="SE">Sweden</country>
</aff><aff id="ehf214713-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>Falun Hospital</institution>
<city>Falun</city>
<country country="SE">Sweden</country>
</aff><aff id="ehf214713-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>Sk&#229;ne University Hospital</institution>
<city>Lund</city>
<country country="SE">Sweden</country>
</aff><aff id="ehf214713-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>Link&#246;ping University Hospital</institution>
<city>Link&#246;ping</city>
<country country="SE">Sweden</country>
</aff><aff id="ehf214713-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>Ume&#229; University Hospital</institution>
<city>Ume&#229;</city>
<country country="SE">Sweden</country>
</aff><aff id="ehf214713-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>Karolinska University Hospital</institution>
<city>Stockholm</city>
<country country="SE">Sweden</country>
</aff><aff id="ehf214713-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>S&#246;dra Hospital</institution>
<city>Stockholm</city>
<country country="SE">Sweden</country>
</aff><aff id="ehf214713-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>&#214;rebro University Hospital</institution>
<city>&#214;rebro</city>
<country country="SE">Sweden</country>
</aff><aff id="ehf214713-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>Danderyd University Hospital</institution>
<city>Stockholm</city>
<country country="SE">Sweden</country>
</aff><aff id="ehf214713-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Cardiology</named-content>
<institution>Uppsala University Hospital</institution>
<city>Uppsala</city>
<country country="SE">Sweden</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence to: Elmir Omerovic, Department of Cardiology, Sahlgrenska University Hospital, Department of Molecular and Clinical Medicine, Sahlgrenska Academy at University of Gothenburg, Bruna str&#229;ket 16, 41345 Gothenburg, Sweden. Email: <email>elmir@wlab.gu.se</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2024</year></pub-date><volume>11</volume><issue seq="400">3</issue><issue-id pub-id-type="pmc-issue-id">462510</issue-id><issue-id pub-id-type="doi">10.1002/ehf2.v11.3</issue-id><fpage>1720</fpage><lpage>1729</lpage><history><date date-type="rev-recd"><day>17</day><month>12</month><year>2023</year></date><date date-type="received"><day>11</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>18</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>07</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>18</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-18 00:25:14.667"><day>18</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Authors. ESC Heart Failure published by John Wiley &amp; Sons Ltd on behalf of European Society of Cardiology.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="EHF2-11-1720.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:EHF2-11-1720.pdf"/><abstract><title>Abstract</title><sec id="ehf214713-sec-0001"><title>Aims</title><p>Takotsubo syndrome (TS) is a heart condition mimicking acute myocardial infarction. TS is characterized by a sudden weakening of the heart muscle, usually triggered by physical or emotional stress. In this study, we aimed to investigate the effect of pharmacological interventions on short&#8208; and long&#8208;term mortality in patients with TS.</p></sec><sec id="ehf214713-sec-0002"><title>Methods and results</title><p>We analysed data from the SWEDEHEART (the Swedish Web System for Enhancement and Development of Evidence&#8208;based care in Heart disease Evaluated According to Recommended Therapies) registry, which included patients who underwent coronary angiography between 2009 and 2016. In total, we identified 1724 patients with TS among 228&#160;263 individuals in the registry. The average age was 66&#160;&#177;&#160;14&#160;years, and 77% were female. Nearly half of the TS patients (49.4%) presented with non&#8208;ST&#8208;elevation acute coronary syndrome, and a quarter (25.9%) presented with ST&#8208;elevation myocardial infarction. Most patients (79.1%) had non&#8208;obstructive coronary artery disease on angiography, while 11.7% had a single&#8208;vessel disease and 9.2% had a multivessel disease. All patients received at least one pharmacological intervention; most of them used beta&#8208;blockers (77.8% orally and 8.3% intravenously) or antiplatelet agents [aspirin (66.7%) and P2Y<sub>12</sub> inhibitors (43.6%)]. According to the Kaplan&#8211;Meier estimator, the probability of all&#8208;cause mortality was 2.5% after 30&#160;days and 16.6% after 6&#160;years. The median follow&#8208;up time was 877&#160;days. Intravenous use of inotropes and diuretics was associated with increased 30&#160;day mortality in TS [hazard ratio (HR)&#160;=&#160;9.92 (<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001) and HR&#160;=&#160;3.22 (<italic toggle="yes">P</italic>&#160;=&#160;0.001), respectively], while angiotensin&#8208;converting enzyme inhibitors and statins were associated with decreased long&#8208;term mortality [HR&#160;=&#160;0.60 (<italic toggle="yes">P</italic>&#160;=&#160;0.025) and HR&#160;=&#160;0.62 (<italic toggle="yes">P</italic>&#160;=&#160;0.040), respectively]. Unfractionated and low&#8208;molecular&#8208;weight heparins were associated with reduced 30&#160;day mortality [HR&#160;=&#160;0.63 (<italic toggle="yes">P</italic>&#160;=&#160;0.01)]. Angiotensin receptor blockers, oral anticoagulants, P2Y<sub>12</sub> antagonists, aspirin, and beta&#8208;blockers did not statistically correlate with mortality.</p></sec><sec id="ehf214713-sec-0003"><title>Conclusions</title><p>Our findings suggest that some medications commonly used to treat TS are associated with higher mortality, while others have lower mortality. These results could inform clinical decision&#8208;making and improve patient outcomes in TS. Further research is warranted to validate these findings and to identify optimal pharmacological interventions for patients with TS.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ehf214713-kwd-0001">Takotsubo syndrome</kwd><kwd id="ehf214713-kwd-0002">Takotsubo cardiomyopathy</kwd><kwd id="ehf214713-kwd-0003">Stress cardiomyopathy</kwd><kwd id="ehf214713-kwd-0004">Pharmacological interventions</kwd><kwd id="ehf214713-kwd-0005">Prognosis</kwd><kwd id="ehf214713-kwd-0006">Mortality</kwd></kwd-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="10"/><word-count count="3778"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.3 mode:remove_FC converted:16.05.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ehf214713-cit-0000"><string-name name-style="western"><surname>Petursson</surname>, <given-names>P.</given-names></string-name>, <string-name name-style="western"><surname>O&#353;tarija&#353;</surname>, <given-names>E.</given-names></string-name>, <string-name name-style="western"><surname>Redfors</surname>, <given-names>B.</given-names></string-name>, <string-name name-style="western"><surname>R&#229;munddal</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>Anger&#229;s</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><surname>V&#246;lz</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Rawshani</surname>, <given-names>A.</given-names></string-name>, <string-name name-style="western"><surname>Hambraeus</surname>, <given-names>K.</given-names></string-name>, <string-name name-style="western"><surname>Koul</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Alfredsson</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western"><surname>Hagstr&#246;m</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Loghman</surname>, <given-names>H.</given-names></string-name>, <string-name name-style="western"><surname>Hofmann</surname>, <given-names>R.</given-names></string-name>, <string-name name-style="western"><surname>Fr&#246;bert</surname>, <given-names>O.</given-names></string-name>, <string-name name-style="western"><surname>Jernberg</surname>, <given-names>T.</given-names></string-name>, <string-name name-style="western"><surname>James</surname>, <given-names>S.</given-names></string-name>, <string-name name-style="western"><surname>Erlinge</surname>, <given-names>D.</given-names></string-name>, and <string-name name-style="western"><surname>Omerovic</surname>, <given-names>E.</given-names></string-name> (<year>2024</year>) <article-title>Effects of pharmacological interventions on mortality in patients with Takotsubo syndrome: a report from the SWEDEHEART registry</article-title>. <source>ESC Heart Failure</source>, <volume>11</volume>: <fpage>1720</fpage>&#8211;<lpage>1729</lpage>. <pub-id pub-id-type="doi">10.1002/ehf2.14713</pub-id>.<pub-id pub-id-type="pmcid">PMC11098647</pub-id><pub-id pub-id-type="pmid">38454651</pub-id></mixed-citation>
</p></notes></front><body id="ehf214713-body-0001"><sec id="ehf214713-sec-0004"><title>Introduction</title><p>Takotsubo syndrome (TS) is a form of heart failure characterized by transitory left ventricular dysfunction and often resembles myocardial infarction (MI) in the acute phase.<xref rid="ehf214713-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="ehf214713-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Several pathophysiological mechanisms, including excessive sympathetic stimulation and myocardial perfusion dysfunction, have been proposed to explain TS.<xref rid="ehf214713-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="ehf214713-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> This syndrome often affects postmenopausal women and poses a differential diagnostic dilemma because it resembles MI. The diagnosis is based mainly on transient akinesia in apical segments detected by ventriculography or cardiac ultrasound without explanatory coronary angiography findings.<xref rid="ehf214713-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="ehf214713-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>Although the medical community first described TS in 1990,<xref rid="ehf214713-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> its importance has significantly increased worldwide in the past decade. As the cause of TS is still unknown, medical professionals have yet to establish the optimal treatment approach.</p><p>Extrapolating pharmacological treatments for acute MI and acute heart failure to TS can be dangerous and may result in severe consequences, including fatalities.<xref rid="ehf214713-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="ehf214713-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> The optimal medical therapy for TS is still unknown, as no randomized controlled clinical trials have been conducted to evaluate the effects of pharmacological interventions.</p><p>Due to the transient nature of the disorder, it will be prudent to concentrate on supportive treatment.<xref rid="ehf214713-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="ehf214713-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> However, pharmacological therapeutic approaches, such as beta&#8208;blockers, antiplatelets, statins, and angiotensin&#8208;converting enzyme inhibitors (ACE&#8208;Is), are frequently used.<xref rid="ehf214713-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ehf214713-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Medical professionals may assume that treatments used for other conditions, such as MI and acute heart failure, will yield similar outcomes in TS.<xref rid="ehf214713-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> However, the efficacy and safety of pharmacological treatments such as inotropes, beta&#8208;blockers, antiplatelets, statins, and ACE&#8208;Is in TS remain unclear.</p><p>We sought to evaluate the effect of pharmacological treatment received during hospitalization and after discharge on short&#8208; and long&#8208;term survival in a large cohort of TS patients using comprehensive national Swedish registry data.</p></sec><sec sec-type="methods" id="ehf214713-sec-0005"><title>Methods</title><sec id="ehf214713-sec-0006"><title>Study population</title><p>We included all hospitalized patients with TS who were reported to the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) between June 2009 and March 2016. TS was defined according to the position statement document from the TS task force of the European Society of Cardiology Heart Failure Association.<xref rid="ehf214713-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> All patients were included in the SCAAR and the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS&#8208;HIA), which are part of the Swedish Web System for Enhancement and Development of Evidence&#8208;based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) registry. It provides a web&#8208;based platform dedicated to data collection from all angiographies and percutaneous coronary interventions performed in coronary catheterization laboratories in Sweden (<italic toggle="yes">n</italic>&#160;=&#160;31) since 1989. The registry is financed by the county councils in Sweden and the Swedish state. The database is continuously merged with the national population registry to obtain information about the patient's vital status. The study was approved by the ethics committee at the University of Gothenburg (Diarienumber 759&#8208;13, date of approval: 6 May 2014).</p></sec><sec id="ehf214713-sec-0007"><title>Definitions</title><p>The SCAAR uses standardized definitions across all hospitals, and all information is entered directly into the database by interventional cardiologists. Since 2009, interventional cardiologists have reported TS based on the criteria (Supporting Information, <italic toggle="yes">Table</italic>
<xref rid="ehf214713-supitem-0001" ref-type="supplementary-material">
<italic toggle="yes">S1</italic>
</xref>). The variables in the SCAAR and RIKS&#8208;HIA registries are routinely validated against patient charts and considered highly accurate. Coronary artery disease is defined as the presence of stenosis&#160;&gt;&#160;50% in any coronary artery.</p><sec id="ehf214713-sec-0008"><title>Endpoints</title><p>We evaluated the association between the received pharmacological treatment and mortality at 30&#160;days and after the long&#8208;term follow&#8208;up. The primary endpoint was mortality at 30&#160;days. Vital status and date of death were obtained from the Swedish National Population Registry until 7 March 2016. The SCAAR was merged with the RIKS&#8208;HIA and the Swedish National Population Registry according to Swedish personal identification numbers. Because the use of unique identification numbers is mandatory, the population registry in Sweden has a high degree of completeness but is not reviewed or adjudicated to establish cardiac vs. non&#8208;cardiac causes of death.</p></sec></sec><sec id="ehf214713-sec-0009"><title>Statistical analysis</title><p>Continuous variables are presented as a median and interquartile range, and categorical variables as frequencies. The normal distribution of variables was assessed by inspecting the distribution of values on histograms and by the Shapiro&#8211;Wilk test.</p><sec id="ehf214713-sec-0010"><title>Imputation protocol</title><p>Our dataset exhibited a missingness rate of 21%, and this was primarily observed in presenting symptoms, electrocardiogram rhythm, electrocardiogram QRS morphology at admission, and smoking status. We employed Little's MCAR test, which assesses whether data are missing completely at random (MCAR).<xref rid="ehf214713-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Our analysis revealed that the missing data in our study were not MCAR, as indicated by the formal test result. Missing values in the dataset were imputed using the missRanger package in R, which utilizes random forest imputation to fill in missing values.<xref rid="ehf214713-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> The missRanger method has been shown to produce accurate imputations while preserving the data distribution, making it a reliable approach to missing data imputation. The imputation procedure and subsequent analyses were done according to Rubin's protocol under the assumption that missing data are missing at random.<xref rid="ehf214713-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</p></sec><sec id="ehf214713-sec-0011"><title>Statistical modelling</title><p>Mortality rates for the entire cohort are presented at 30 days and over the long term. After imputation of missing data, multivariable Cox proportional hazards were used to adjust for differences in patient characteristics. All multivariable models were fit to the entire study cohort and were adjusted for variables in <italic toggle="yes">Table</italic>
<xref rid="ehf214713-tbl-0001" ref-type="table">
<italic toggle="yes">1</italic>
</xref>, Killip class, the use of an intra&#8208;aortic balloon counterpulsation pump, and duration of hospitalization. The treating hospital was included as a random effect variable to account for the clustering of patients within hospitals. To prevent immortal time bias when evaluating long&#8208;term mortality, the follow&#8208;up period began on the date after the discharge.<xref rid="ehf214713-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Every analysis used the commonly established criterion of statistical significance, which is a two&#8208;tailed <italic toggle="yes">P</italic> value of 0.05. All statistical computations and data visualization were done in R, Version 4.2.3 (R Foundation for Statistical Computing), and Stata (release 18.0, StataCorp LLC, College Station, TX, USA). Schoenfeld residuals were used to assess proportional hazards.<xref rid="ehf214713-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> The variable hospital stay violated the assumption of a proportional hazard. To address this violation, a time&#8208;varying Cox regression model<xref rid="ehf214713-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> was employed, allowing the effect of the variable to change over time. To account for non&#8208;linear age&#8211;hazard relationships, age was represented as a spline with three knots.</p><table-wrap position="float" id="ehf214713-tbl-0001" content-type="Table" orientation="portrait"><label>Table 1</label><caption><p>Patients' characteristics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="center" valign="bottom" rowspan="1" colspan="1">Value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Female gender (%)</td><td align="center" valign="top" rowspan="1" colspan="1">77.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (&#177;SD), years</td><td align="center" valign="top" rowspan="1" colspan="1">66&#160;&#177;&#160;14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes (%)</td><td align="center" valign="top" rowspan="1" colspan="1">10.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension (%)</td><td align="center" valign="top" rowspan="1" colspan="1">44.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hyperlipidaemia (%)</td><td align="center" valign="top" rowspan="1" colspan="1">25.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking status (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Current smoker</td><td align="center" valign="top" rowspan="1" colspan="1">16.4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Previous smoker</td><td align="center" valign="top" rowspan="1" colspan="1">28.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Previous myocardial infarction</td><td align="center" valign="top" rowspan="1" colspan="1">5.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Previous percutaneous coronary intervention</td><td align="center" valign="top" rowspan="1" colspan="1">2.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Killip class I</td><td align="center" valign="top" rowspan="1" colspan="1">89.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Previous coronary artery bypass surgery</td><td align="center" valign="top" rowspan="1" colspan="1">1.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Extent of coronary artery disease (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Normal/non&#8208;obstructive</td><td align="center" valign="top" rowspan="1" colspan="1">79.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Single vessel</td><td align="center" valign="top" rowspan="1" colspan="1">11.7</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Multivessel</td><td align="center" valign="top" rowspan="1" colspan="1">9.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pharmacological treatment at admission (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Beta&#8208;blockers</td><td align="center" valign="top" rowspan="1" colspan="1">27.8</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Angiotensin&#8208;converting enzyme inhibitors</td><td align="center" valign="top" rowspan="1" colspan="1">19.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Angiotensin receptor blockers</td><td align="center" valign="top" rowspan="1" colspan="1">3.8</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Calcium antagonists</td><td align="center" valign="top" rowspan="1" colspan="1">10.4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diuretics</td><td align="center" valign="top" rowspan="1" colspan="1">16.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Aspirin</td><td align="center" valign="top" rowspan="1" colspan="1">24.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Oral anticoagulants</td><td align="center" valign="top" rowspan="1" colspan="1">4.4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Statins</td><td align="center" valign="top" rowspan="1" colspan="1">22.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other lipid&#8208;lowering agents</td><td align="center" valign="top" rowspan="1" colspan="1">1.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Digitalis</td><td align="center" valign="top" rowspan="1" colspan="1">1.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Symptoms at admission (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Chest pain</td><td align="center" valign="top" rowspan="1" colspan="1">76.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Dyspnoea</td><td align="center" valign="top" rowspan="1" colspan="1">9.8</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cardiac arrest</td><td align="center" valign="top" rowspan="1" colspan="1">1.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">12.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ECG rhythm</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sinus</td><td align="center" valign="top" rowspan="1" colspan="1">92.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Atrial fibrillation/flutter</td><td align="center" valign="top" rowspan="1" colspan="1">5.4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">2.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ECG QRS morphology at admission (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Normal</td><td align="center" valign="top" rowspan="1" colspan="1">72.2</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pacemaker</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Left bundle branch block</td><td align="center" valign="top" rowspan="1" colspan="1">7.3</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Right bundle branch block</td><td align="center" valign="top" rowspan="1" colspan="1">2.5</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Q&#8208;wave</td><td align="center" valign="top" rowspan="1" colspan="1">8.6</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">8.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ECG ST&#8208;T segment at admission (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Normal</td><td align="center" valign="top" rowspan="1" colspan="1">28.9</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ST&#8208;elevation</td><td align="center" valign="top" rowspan="1" colspan="1">31.7</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ST&#8208;depression</td><td align="center" valign="top" rowspan="1" colspan="1">12.4</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">T&#8208;wave negative</td><td align="center" valign="top" rowspan="1" colspan="1">13.1</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">13.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Laboratory status</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Haemoglobin (g/L)</td><td align="center" valign="top" rowspan="1" colspan="1">137&#160;&#177;&#160;15</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Glucose (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">7.82&#160;&#177;&#160;3.45</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">C&#8208;reactive protein (mg/L)</td><td align="center" valign="top" rowspan="1" colspan="1">15&#160;&#177;&#160;34</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Creatinine (&#956;mol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">78&#160;&#177;&#160;55</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cholesterol (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">5.04&#160;&#177;&#160;1.18</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Low&#8208;density lipoprotein (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">3.03&#160;&#177;&#160;1.00</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">High&#8208;density lipoprotein (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">1.47&#160;&#177;&#160;0.49</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Troponin T (ng)</td><td align="center" valign="top" rowspan="1" colspan="1">730&#160;&#177;&#160;1230</td></tr></tbody></table><table-wrap-foot id="ehf214713-ntgp-0001"><fn id="ehf214713-note-0001"><p>ECG, electrocardiogram; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="ehf214713-sec-0012"><title>Sensitivity analyses and post&#8208;estimation diagnostics</title><p>Sensitivity tests were conducted to determine the extent to which an unmeasured variable may cause exposure to different treatments to lose statistical significance.<xref rid="ehf214713-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> We utilized the tipr package<xref rid="ehf214713-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> in R to quantitatively assess the potential impact of unmeasured confounding. This approach evaluated the closest observed confidence interval bound to the null from our primary analysis, along with plausible effect sizes for an unmeasured confounder on both the outcome and the exposure. This tipping point analysis calculated the strength an unmeasured confounder would need to possess to nullify our observed association. The goodness of fit of the models was assessed with Harrell's <italic toggle="yes">C</italic>&#8208;test.<xref rid="ehf214713-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Multicollinearity between the variables in the model was evaluated by calculating the variance inflation factor (VIF).</p></sec></sec></sec><sec sec-type="results" id="ehf214713-sec-0013"><title>Results</title><sec id="ehf214713-sec-0014"><title>Patient characteristics and treatments</title><p>In total, we identified 1724 patients with TS among 228&#160;263 unique individuals who underwent coronary angiography and were reported to the SCAAR registry between 2009 and 2016 (<italic toggle="yes">Figure</italic>&#160;<xref rid="ehf214713-fig-0001" ref-type="fig">
<italic toggle="yes">1</italic>
</xref>). The characteristics of the hospitalized patients, including their pharmacological treatment, are presented in <italic toggle="yes">Table</italic>
<xref rid="ehf214713-tbl-0001" ref-type="table">
<italic toggle="yes">1</italic>
</xref>. Seventy&#8208;seven per cent of patients were female. The average age was 66&#160;&#177;&#160;14&#160;years, and diabetes (10.4%), hypertension (44.3%), and hyperlipidaemia (25.5%) were the most frequent comorbidities. According to smoking status, 16.4% were current smokers, while 28.5% were previous smokers.</p><fig position="float" fig-type="Figure" id="ehf214713-fig-0001" orientation="portrait"><label>Figure 1</label><caption><p>Patient selection chart for Takotsubo syndrome (TS) cases in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). The study aimed to identify TS cases among patients who underwent coronary angiography and were reported to the SCAAR registry between 2009 and 2016. A total of 1724 patients with TS were identified among 228&#160;263 unique individuals who underwent coronary angiography during the study period. Categorization into the groups stable angina, unstable angina/non&#8208;ST&#8208;elevation myocardial infarction (UA/NSTEMI), ST&#8208;elevation myocardial infarction (STEMI), and other is based on the initial indication for coronary angiography. Initial indications for angiography are guided by early clinical signs, laboratory markers of cell necrosis, and electrocardiogram findings.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="EHF2-11-1720-g001.jpg"/></fig><p>In half (49.4%) of the 1724 patients, the indication for coronary angiography was non&#8208;ST&#8208;elevation acute coronary syndrome, which includes unstable angina and non&#8208;ST&#8208;elevation MI. The remainder were reported as ST&#8208;elevation MI (25.9%), stable angina (4.3%), and other diagnoses (20.4%), including cardiac arrest, heart failure, valve disease, chest pain, and arrhythmias. Killip I accounted for the majority of patients (88.9%), followed by Killip II (7.8%), Killip III (2.1%), and Killip IV (1.2%).</p><p>A total of 5.9% of patients had a history of MI, 2.9% had percutaneous coronary intervention, and 1.6% had undergone coronary artery bypass graft treatment. Coronary angiography revealed that most patients (79.1%) had normal coronaries or non&#8208;obstructive disease, while 11.7% had a single&#8208;vessel disease and 9.9% had a multivessel disease.</p><p>Before hospitalization, a considerable number of patients were already using beta&#8208;blockers (27.8%), ACE&#8208;Is (19.1%), and calcium antagonists (10.4%). Additionally, 16.1% of patients were using diuretics, 24.5% were taking aspirin, and 4.4% were taking oral anticoagulants. In addition, 22.3% of patients were already taking statins, whereas a small percentage were getting other lipid&#8208;lowering medications and digoxin, respectively.</p><p>All patients received at least one pharmaceutical intervention during hospitalization (<italic toggle="yes">Table</italic>&#160;<xref rid="ehf214713-tbl-0002" ref-type="table">
<italic toggle="yes">2</italic>
</xref>). Most were given beta&#8208;blockers (77.8% orally and 8.3% intravenously) and antiplatelet medications [aspirin (66.7%) and P2Y<sub>12</sub> inhibitors (43.6%)]. Other medications included unfractionated and low&#8208;molecular&#8208;weight heparins (UH/LMWH) (65.3%), oral anticoagulants (11.3%), ACE&#8208;Is (55.5%), angiotensin receptor blockers (ARBs) (15.3%), statins (55.1%), diuretics (19.5% orally and 17.2% intravenously), inotropes (3.8%), and digoxin (1.3%). An intra&#8208;aortic balloon counterpulsation pump was used at 0.5%. The median duration of hospitalization was 4&#160;days, with an interquartile range of 4 (<italic toggle="yes">Figure</italic>&#160;<xref rid="ehf214713-fig-0002" ref-type="fig">
<italic toggle="yes">2</italic>
</xref>).</p><table-wrap position="float" id="ehf214713-tbl-0002" content-type="Table" orientation="portrait"><label>Table 2</label><caption><p>In&#8208;hospital treatment</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="left" valign="bottom" rowspan="1" colspan="1">Percentage</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Inotropes i.v.</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diuretics i.v.</td><td align="char" char="." valign="top" rowspan="1" colspan="1">17.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diuretics p.o.</td><td align="char" char="." valign="top" rowspan="1" colspan="1">19.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Digoxin p.o.</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unfractionated heparins/low&#8208;molecular&#8208;weight heparins</td><td align="char" char="." valign="top" rowspan="1" colspan="1">65.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Statins</td><td align="char" char="." valign="top" rowspan="1" colspan="1">55.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Angiotensin&#8208;converting enzyme inhibitors</td><td align="char" char="." valign="top" rowspan="1" colspan="1">55.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Angiotensin receptor blockers</td><td align="char" char="." valign="top" rowspan="1" colspan="1">15.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beta&#8208;blockers i.v.</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beta&#8208;blockers p.o.</td><td align="char" char="." valign="top" rowspan="1" colspan="1">77.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aspirin</td><td align="char" char="." valign="top" rowspan="1" colspan="1">66.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Intra&#8208;aortic balloon counterpulsation pump</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.5</td></tr></tbody></table><table-wrap-foot id="ehf214713-ntgp-0002"><fn id="ehf214713-note-0002"><p>i.v., intravenous; p.o, per oral.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="Figure" id="ehf214713-fig-0002" orientation="portrait"><label>Figure 2</label><caption><p>The Kaplan&#8211;Meier curve illustrates the 30&#160;day (A) and long&#8208;term mortality (B) rates among patients diagnosed with Takotsubo syndrome. The median follow&#8208;up duration of patients was 877&#160;days (interquartile range: 383&#8211;1544), and the crude all&#8208;cause mortality rates were found to be 3.9% and 16.7% at 30&#160;day and long&#8208;term follow&#8208;up, respectively. Notably, the Kaplan&#8211;Meier curve demonstrated that the short&#8208; and long&#8208;term mortality rates for patients with Takotsubo syndrome are comparable with those observed among patients with myocardial infarction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="EHF2-11-1720-g003.jpg"/></fig></sec><sec id="ehf214713-sec-0015"><title>Clinical outcomes</title><p>The median follow&#8208;up time was 877&#160;days (interquartile range: 383&#8211;1544). According to the Kaplan&#8211;Meier estimator, the probability of all&#8208;cause mortality was 2.5% after 30&#160;days and 16.6% after 6&#160;years.</p><p>Pharmacological interventions associated with increased mortality in TS included intravenous use of inotropes and diuretics and orally administered digoxin (<italic toggle="yes">Figure</italic>
<xref rid="ehf214713-fig-0003" ref-type="fig">
<italic toggle="yes">3</italic>
<italic toggle="yes">A</italic>
</xref>). Treatment with statins and UH/LMWH was associated with lower 30&#160;day mortality, while statins and ACE&#8208;Is were associated with lower long&#8208;term mortality (<italic toggle="yes">Figure</italic>
<xref rid="ehf214713-fig-0003" ref-type="fig">
<italic toggle="yes">3</italic>
<italic toggle="yes">B</italic>
</xref>). Medications that did not show a statistically significant association with mortality were ARBs, oral anticoagulants, P2Y<sub>12</sub> antagonists, aspirin, and beta&#8208;blockers (<italic toggle="yes">Figure</italic>
<xref rid="ehf214713-fig-0003" ref-type="fig">
<italic toggle="yes">3</italic>
<italic toggle="yes">C</italic>
</xref>).</p><fig position="float" fig-type="Figure" id="ehf214713-fig-0003" orientation="portrait"><label>Figure 3</label><caption><p>Pharmacological interventions and mortality rates in patients with Takotsubo syndrome (TS): associations and outcomes. This figure comprises three panels displaying the associations between different pharmacological interventions and mortality rates among patients diagnosed with TS. Panel (A) indicates the use of intravenous inotrope, intravenous diuretics, and orally administered digoxin, which were associated with increased mortality rates. Panel (B) displays the use of angiotensin&#8208;converting enzyme inhibitors (ACE&#8208;Is) and statins, which were found to be associated with decreased long&#8208;term mortality rates. Furthermore, the use of unfractionated and low&#8208;molecular&#8208;weight heparins (UH/LMWH) was associated with reduced 30&#160;day mortality rates. Panel (C) shows that several medications, including angiotensin receptor blockers (ARBs), oral anticoagulants, P2Y<sub>12</sub> antagonists, aspirin, and beta&#8208;blockers (both intravenous and oral), did not exhibit a statistically significant association with mortality rates in TS patients. Due to the wide 95% confidence interval (CI), risk estimates for ARBs, aspirin, and orally and intravenously administered beta&#8208;blockers are inconclusive. HR, hazard ratio; i.v., intravenous; p.o, per oral.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="EHF2-11-1720-g002.jpg"/></fig></sec><sec id="ehf214713-sec-0016"><title>Sensitivity analyses and post&#8208;estimation diagnostics</title><p>The time&#8208;varying Cox regression model showed good predictive accuracy, with Harrell's <italic toggle="yes">C</italic>&#8208;index of 0.888, indicating the model's good discrimination ability. We detected collinearity between the variables sex and age, with a VIF of 26 (a VIF&#160;&gt;&#160;5 indicating collinearity), and thus, we excluded sex from the model. There was no evidence of collinearity among the other predictor variables. The sensitivity analysis results are displayed in <italic toggle="yes">Table</italic>
<xref rid="ehf214713-tbl-0003" ref-type="table">
<italic toggle="yes">3</italic>
</xref>, indicating that the use of inotropes has the strongest association with mortality. To lose its statistical significance as an independent predictor of death at 30&#160;days, an unmeasured confounder must have a risk ratio above 10. This is based on a prevalence of 70% in the inotrope&#8208;exposed group and 10% in the inotrope&#8208;unexposed group.</p><table-wrap position="float" id="ehf214713-tbl-0003" content-type="Table" orientation="portrait"><label>Table 3</label><caption><p>Results of sensitivity analyses assessing the impact of unmeasured confounding on treatment&#8211;mortality associations</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">RR</th><th align="center" valign="bottom" rowspan="1" colspan="1">P<sub>Treated</sub> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">P<sub>Untreated</sub> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Inotropes i.v.</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">70</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diuretics i.v.</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">80</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diuretics p.o.</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">30</td><td align="center" valign="top" rowspan="1" colspan="1">20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Digoxin</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">60</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unfractionated heparins/low&#8208;molecular&#8208;weight heparins</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">90</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Statins</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">20</td><td align="center" valign="top" rowspan="1" colspan="1">30</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACE&#8208;Is</td><td align="center" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">20</td></tr></tbody></table><table-wrap-foot id="ehf214713-ntgp-0003"><fn id="ehf214713-note-0003"><p>ACE&#8208;Is, angiotensin&#8208;converting enzyme inhibitors; i.v., intravenous; p.o, per oral; RR, relative risk for association between the unmeasured confounder and mortality.</p></fn><fn id="ehf214713-note-0004"><p>Interpretation: When adjusting for unmeasured confounding, the upper or lower limit of the 95% confidence interval for mortality would cross null, losing significance with the specific treatment if the unmeasured confounder had a risk of mortality above the specific RR, considering the corresponding prevalence in the treated group (P<sub>Treated</sub>) and the untreated group (P<sub>Untreated</sub>). For example, to lose statistical significance as an independent predictor of death at 30&#160;days, an unmeasured confounder would need to have a risk ratio above 10, with a prevalence of 70% in the inotrope&#8208;exposed group and 10% in the inotrope&#8208;unexposed group.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="ehf214713-sec-0017"><title>Discussion</title><p>Using data from the SWEDEHEART registry, we analysed the effect of pharmacological therapy on mortality in a large cohort of 1724 individuals with TS. Inotropes, diuretics, anticoagulants, ACE&#8208;Is, and statins were significantly associated with short&#8208; and long&#8208;term mortality among TS patients. ACE&#8208;Is, statins, and UH/LMWH were associated with lower mortality in TS, whereas the opposite was noted for inotropes, diuretics, and digoxin. Aspirin, beta&#8208;blockers, ARBs, P2Y<sub>12</sub> antagonists, and oral anticoagulants were neutral.</p><p>Previous studies<xref rid="ehf214713-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="ehf214713-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="ehf214713-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> have indicated that the mortality rates in patients with TS are comparable with those observed in patients with MI. However, there appears to be a significant disparity in mortality rates between different countries and even within the same country across different regions.<xref rid="ehf214713-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> It is reasonable to hypothesize that differences in pharmacological interventions employed in managing TS may partly contribute to this variation.<xref rid="ehf214713-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
</p><p>Researchers have evaluated multiple therapies in various study designs, including retrospective cohorts, case series, and meta&#8208;analyses. Beta&#8208;blockers, ACE&#8208;Is/ARBs, and antiplatelets are the most frequently evaluated drugs. Except for some reports showing the possible therapeutic effect of levosimendan<xref rid="ehf214713-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> and ACE&#8208;I/ARB,<xref rid="ehf214713-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="ehf214713-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> the evidence for effective treatment of TS is scarce. Given the pathophysiological role of catecholamines in TS, treatment with beta&#8208;blockers may seem logical. However, only limited evidence supports using beta&#8208;blockers<xref rid="ehf214713-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> in these patients.</p><p>One of the most important findings of our study is that inotropes are strongly associated with increased mortality in TS. It is reasonable to think that inotropes were mainly used in TS patients with haemodynamic instability. However, it is crucial to keep in mind that inotropes may aggravate heart failure in patients with TS. This is consistent with the prevailing theory concerning the pathophysiology of TS, where catecholamines play an essential role in forming typical akinesia in apical segments. There is solid evidence that administering catecholamines to humans<xref rid="ehf214713-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> and animals<xref rid="ehf214713-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> causes the TS phenotype. Some data support the idea that levosimendan, a phosphodiesterase inhibitor with both inotropic and vasodilatory effects, might benefit the recovery of TS.<xref rid="ehf214713-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> However, caution should be taken with all interventions reducing afterload in TS because ~25% of these patients may have left ventricular outflow tract obstruction.<xref rid="ehf214713-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Both inotropic and vasodilating treatments can be detrimental in patients with left ventricular outflow tract obstruction and haemodynamic instability.<xref rid="ehf214713-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> In addition, there is experimental evidence against using levosimendan in TS.<xref rid="ehf214713-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Our study confirms these observations, as utilizing inotropes was associated with the highest risk of dying within 30&#160;days.</p><p>An increased risk of death was associated with the use of diuretics. In patients with acute heart failure, high&#8208;dose diuretics or aggressive diuresis may exacerbate renal function, electrolyte abnormalities, and central haemodynamics.<xref rid="ehf214713-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> Diuretic&#8208;induced hypovolaemia may be more harmful in TS patients with left ventricular outflow tract obstruction. Many patients with TS also have decreased peripheral vascular resistance,<xref rid="ehf214713-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> and diuretic therapy may aggravate volume depletion and haemodynamic instability. Diuretics can also activate the sympathetic nervous system, which may be deleterious in TS as an overactivated sympathetic system and high catecholamine levels are regarded as central to TS pathophysiology.<xref rid="ehf214713-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</p><p>Antiplatelet therapy was assessed in a recently published meta&#8208;analysis,<xref rid="ehf214713-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> with evidence suggesting its association with adverse outcomes; however, one study seemed to have influenced the conclusion. Aspirin and P2Y<sub>12</sub> inhibitors did not significantly associate with mortality. On the other hand, we discovered that anticoagulant therapy with UH/LMWH was associated with lower mortality. The relatively common thrombo&#8208;embolism observed in these individuals may be explained by a condition of blood hyperviscosity documented in the acute phase of TS.<xref rid="ehf214713-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="ehf214713-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> More research is required to fully understand the potential preventive benefits of anticoagulation during the acute phase of TS.</p><p>In our study, ACE&#8208;Is were associated with decreased long&#8208;term mortality, while ARBs were not. A lack of power to show a statistically significant association may explain this discrepancy, as relatively few patients received ARBs. However, although commonly grouped because of their analogous inhibitory mechanism on the renin&#8208;angiotensin system, ACE&#8208;Is and ARBs have different sites of action. ACE&#8208;Is block the conversion of angiotensin I to angiotensin II by inhibiting the ACE, while ARBs block the binding of angiotensin II to the angiotensin II type 1 receptor. While both medications effectively reduce the activation of the renin&#8208;angiotensin&#8208;aldosterone system, ACE&#8208;Is may also affect the breakdown of other substances, such as bradykinin, which can lead to an increase in vasodilation and may have additional cardioprotective effects, such as inhibition of the central sympathetic system. ARBs, conversely, are more selective in their target receptor and may have less effect on other pathways. Another explanation is related to differences in dosing and individual patient characteristics. ACE&#8208;Is and ARBs may be prescribed at different doses depending on the patients' characteristics, such as age, sex, comorbidities, and overall health status. These differences in dosing could contribute to differences in effectiveness and impact on survival. This observation is at least indirectly supported by a meta&#8208;analysis in heart failure patients in which ACE&#8208;Is, but not ARBs, reduced all&#8208;cause mortality and cardiovascular deaths.<xref rid="ehf214713-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
</p><p>Despite being favourable in our assessment of TS, statins have not been well explored so far. To the best of our knowledge, no other investigation has reported a favourable connection with mortality in TS. Statins have anti&#8208;inflammatory properties, and TS is thought to be associated with the complex interplay of inflammatory processes. By reducing inflammation, statins may help moderate some of the underlying pathophysiological mechanisms involved in TS, improving outcomes. Second, statins are commonly prescribed for their cholesterol&#8208;lowering effects, but they may also have additional benefits for the cardiovascular system, such as improving endothelial function and reducing oxidative stress. These effects may help to improve overall cardiovascular health and reduce the risk of complications in patients with TS. Hypertension, diabetes, and hyperlipidaemia are common comorbidities associated with TS. Statins are frequently prescribed for managing these comorbidities; therefore, patients with TS who are already taking statins may have better control of their underlying conditions, which may improve survival.</p><p>The data obtained from the SWEDEHEART registry are unique because of their nationwide coverage and high&#8208;quality input. Selection bias, usually attributed to observational studies, can be considered low in our study due to the inclusion of the entire population compared with sample&#8208;based studies. However, several limitations of the registry need to be addressed. Because of the registry's observational and non&#8208;experimental nature, no definitive causal relationship between pharmacological interventions and mortality can be made. The lack of detailed information on the route of administration, daily doses, and length of treatment makes interpretations of any association between a drug class and outcome challenging. To increase the level of evidence and establish a causal relationship between the pharmacological interventions and mortality in TS, more research should be conducted, ideally with patients randomly assigned to a pre&#8208;specified intervention in a randomized controlled trial. The ongoing BROKEN SWEDEHEART study<xref rid="ehf214713-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> with a 2&#160;&#215;&#160;2 factorial design will evaluate whether adenosine/dipyridamole and apixaban improve contractile recovery and decrease major adverse cardiovascular events at 30&#160;days.</p><p>Even though TS is self&#8208;healing in most cases, it can manifest as life&#8208;threatening heart failure in the worst&#8208;case scenario. Some of the results of our analysis are consistent with previously reported observations, supporting the hypothesis that specific pharmacological treatments may be beneficial while others may be harmful. To clarify this matter, it is necessary to conduct high&#8208;quality randomized controlled trials and observational studies. In the meantime, it is advisable to exercise caution when implementing pharmacological interventions, adhering to the fundamental principle of &#8216;primum nil nocere&#8217; (first, do no harm).</p></sec><sec sec-type="COI-statement" id="ehf214713-sec-0018"><title>Conflict of interest</title><p>None declared.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="ehf214713-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table S1.</bold> Definition of takotsubo syndrome used in the Swedish Coronary Angiography and Angioplasty Registry.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="EHF2-11-1720-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ref-list id="ehf214713-bibl-0001" content-type="cited-references"><title>References</title><ref id="ehf214713-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ehf214713-cit-0002"><string-name name-style="western"><surname>Lyon</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Bossone</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Sechtem</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Citro</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Underwood</surname><given-names>SR</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Current state of knowledge on Takotsubo syndrome: A position statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology</article-title>. <source>Eur J Heart Fail</source><year>2016</year>;<volume>18</volume>:<fpage>8</fpage>&#8208;<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ejhf.424</pub-id><pub-id pub-id-type="pmid">26548803</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ehf214713-cit-0003"><string-name name-style="western"><surname>Lyon</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Citro</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Morel</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Ghadri</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Templin</surname><given-names>C</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Pathophysiology of Takotsubo syndrome: JACC state&#8208;of&#8208;the&#8208;art review</article-title>. <source>J Am Coll Cardiol</source><year>2021</year>;<volume>77</volume>:<fpage>902</fpage>&#8208;<lpage>921</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2020.10.060</pub-id><pub-id pub-id-type="pmid">33602474</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ehf214713-cit-0004"><string-name name-style="western"><surname>Ghadri</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Wittstein</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Prasad</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sharkey</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dote</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Akashi</surname><given-names>YJ</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>International expert consensus document on Takotsubo syndrome (part I): Clinical characteristics, diagnostic criteria, and pathophysiology</article-title>. <source>Eur Heart J</source><year>2018</year>;<volume>39</volume>:<fpage>2032</fpage>&#8208;<lpage>2046</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehy076</pub-id><pub-id pub-id-type="pmid">29850871</pub-id><pub-id pub-id-type="pmcid">PMC5991216</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ehf214713-cit-0005"><string-name name-style="western"><surname>Dote</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tateishi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Uchida</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ishihara</surname><given-names>M</given-names></string-name>. <article-title>Myocardial stunning due to simultaneous multivessel coronary spasms: A review of 5 cases</article-title>. <source>J Cardiol</source><year>1991</year>;<volume>21</volume>:<fpage>203</fpage>&#8208;<lpage>214</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jmv.29003</pub-id><pub-id pub-id-type="pmid">1841907</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ehf214713-cit-0006"><string-name name-style="western"><surname>Redfors</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Omerovic</surname><given-names>E</given-names></string-name>. <article-title>Stress&#8208;induced cardiomyopathy in a patient with chronic spinal cord transection at the level of C5: Endocrinologically mediated catecholamine toxicity</article-title>. <source>Int J Cardiol</source><year>2012</year>;<volume>159</volume>:<fpage>e61</fpage>&#8208;<lpage>e62</lpage>. (In English). doi:<pub-id pub-id-type="doi">10.1016/j.ijcard.2011.12.025</pub-id><pub-id pub-id-type="pmid">22240764</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ehf214713-cit-0007"><string-name name-style="western"><surname>Redfors</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Omerovic</surname><given-names>E</given-names></string-name>. <article-title>Stress&#8208;induced cardiomyopathy in the critically ill&#8212;Why inotropes fail to improve outcome</article-title>. <source>Int J Cardiol</source><year>2013</year>;<volume>168</volume>:<fpage>4489</fpage>&#8208;<lpage>4490</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijcard.2013.06.128</pub-id><pub-id pub-id-type="pmid">23871615</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ehf214713-cit-0008"><string-name name-style="western"><surname>Omerovic</surname><given-names>E</given-names></string-name>. <article-title>Takotsubo syndrome&#8212;Scientific basis for current treatment strategies</article-title>. <source>Heart Fail Clin</source><year>2016</year>;<volume>12</volume>:<fpage>577</fpage>&#8208;<lpage>586</lpage>. (Review). doi:<pub-id pub-id-type="doi">10.1016/j.hfc.2016.06.008</pub-id><pub-id pub-id-type="pmid">27638027</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ehf214713-cit-0009"><string-name name-style="western"><surname>Kato</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lyon</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Ghadri</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Templin</surname><given-names>C</given-names></string-name>. <article-title>Takotsubo syndrome: Aetiology, presentation and treatment</article-title>. <source>Heart</source><year>2017</year>;<volume>103</volume>:<fpage>1461</fpage>&#8208;<lpage>1469</lpage>. (In eng). doi:<pub-id pub-id-type="doi">10.1136/heartjnl-2016-309783</pub-id><pub-id pub-id-type="pmid">28839096</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ehf214713-cit-0010"><string-name name-style="western"><surname>Sethi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Murli</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kaiwan</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Vora</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Chopra</surname><given-names>H</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Broken heart syndrome: Evolving molecular mechanisms and principles of management</article-title>. <source>J Clin Med</source><year>2022</year>;<volume>12</volume>:<fpage>125</fpage>. (In eng). doi:<pub-id pub-id-type="doi">10.3390/jcm12010125</pub-id><pub-id pub-id-type="pmid">36614928</pub-id><pub-id pub-id-type="pmcid">PMC9821117</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ehf214713-cit-0011"><string-name name-style="western"><surname>Omerovic</surname><given-names>E</given-names></string-name>. <article-title>How to think about stress&#8208;induced cardiomyopathy?&#8212;Think out of the box!</article-title><source>Scand Cardiovasc J</source><year>2011</year>;<volume>45</volume>:<fpage>67</fpage>&#8208;<lpage>71</lpage>. (Review). doi:<pub-id pub-id-type="doi">10.3109/14017431.2011.565794</pub-id><pub-id pub-id-type="pmid">21401402</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ehf214713-cit-0012"><string-name name-style="western"><surname>Little</surname><given-names>RJA</given-names></string-name>. <article-title>A test of missing completely at random for multivariate data with missing values</article-title>. <source>J Am Stat Assoc</source><year>1988</year>;<volume>83</volume>:<fpage>1198</fpage>&#8208;<lpage>1202</lpage>. (In en). doi:<pub-id pub-id-type="doi">10.1080/01621459.1988.10478722</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ehf214713-cit-0013"><string-name name-style="western"><surname>Stekhoven</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Buhlmann</surname><given-names>P</given-names></string-name>. <article-title>MissForest&#8212;Non&#8208;parametric missing value imputation for mixed&#8208;type data</article-title>. <source>Bioinformatics</source><year>2012</year>;<volume>28</volume>:<fpage>112</fpage>&#8208;<lpage>118</lpage>. doi:<pub-id pub-id-type="doi">10.1093/bioinformatics/btr597</pub-id><pub-id pub-id-type="pmid">22039212</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ehf214713-cit-0014"><string-name name-style="western"><surname>Rubin</surname><given-names>DB</given-names></string-name>. <article-title>Inference and missing data</article-title>. <source>Biometrika</source><year>1976</year>;<volume>63</volume>:<fpage>581</fpage>&#8208;<lpage>592</lpage>. doi:<pub-id pub-id-type="doi">10.1093/biomet/63.3.581</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ehf214713-cit-0015"><string-name name-style="western"><surname>Anderson</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Cain</surname><given-names>KC</given-names></string-name>, <string-name name-style="western"><surname>Gelber</surname><given-names>RD</given-names></string-name>. <article-title>Analysis of survival by tumor response</article-title>. <source>J Clin Oncol</source><year>1983</year>;<volume>1</volume>:<fpage>710</fpage>&#8208;<lpage>719</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.1983.1.11.710</pub-id><pub-id pub-id-type="pmid">6668489</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ehf214713-cit-0016"><string-name name-style="western"><surname>Schoenfeld</surname><given-names>D</given-names></string-name>. <article-title>Partial residuals for the proportional hazards regression model</article-title>. <source>Biometrika</source><year>1982</year>;<volume>69</volume>:<fpage>239</fpage>&#8208;<lpage>241</lpage>. doi:<pub-id pub-id-type="doi">10.1093/biomet/69.1.239</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0016"><label>16</label><mixed-citation publication-type="book" id="ehf214713-cit-0017"><string-name name-style="western"><surname>Therneau</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Grambsch</surname><given-names>P</given-names></string-name>. <source>Modeling Survival Data: Extending the Cox Model</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer CrossRef</publisher-name>; <year>2000</year>.</mixed-citation></ref><ref id="ehf214713-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ehf214713-cit-0018"><string-name name-style="western"><surname>Schneeweiss</surname><given-names>S</given-names></string-name>. <article-title>Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics</article-title>. <source>Pharmacoepidemiol Drug Saf</source><year>2006</year>;<volume>15</volume>:<fpage>291</fpage>&#8208;<lpage>303</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.1200</pub-id><pub-id pub-id-type="pmid">16447304</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ehf214713-cit-0019"><string-name name-style="western"><surname>McGowan</surname><given-names>LDA</given-names></string-name>. <article-title>tipr: An R package for sensitivity analyses for unmeasured confounders</article-title>. <source>J Open Sourc Soft</source><year>2022</year>;<volume>7</volume>:<elocation-id>4495</elocation-id>. doi:<pub-id pub-id-type="doi">10.21105/joss.04495</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0019"><label>19</label><mixed-citation publication-type="book" id="ehf214713-cit-0020"><string-name name-style="western"><surname>Frank</surname><given-names>EH</given-names></string-name>. <source>Regression Modeling Strategies With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis</source>. <publisher-name>Spinger</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="ehf214713-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ehf214713-cit-0021"><string-name name-style="western"><surname>Butt</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Bang</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>R&#248;rth</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kristensen</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Yafasova</surname><given-names>A</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Long&#8208;term risk of death and hospitalization in patients with heart failure and Takotsubo syndrome: Insights from a nationwide cohort</article-title>. <source>J Card Fail</source><year>2022</year>;<volume>28</volume>:<fpage>1534</fpage>&#8208;<lpage>1544</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cardfail.2022.02.002</pub-id><pub-id pub-id-type="pmid">35167917</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ehf214713-cit-0022"><string-name name-style="western"><surname>Looi</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Webster</surname><given-names>MWI</given-names></string-name>, <string-name name-style="western"><surname>To</surname><given-names>ACY</given-names></string-name>, <string-name name-style="western"><surname>Kerr</surname><given-names>AJ</given-names></string-name>. <article-title>Postdischarge outcome after Takotsubo syndrome compared with patients post&#8208;ACS and those without prior CVD: ANZACS&#8208;QI 19</article-title>. <source>Open Heart</source><year>2018</year>;<volume>5</volume>:<elocation-id>e000918</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/openhrt-2018-000918</pub-id><pub-id pub-id-type="pmid">30564377</pub-id><pub-id pub-id-type="pmcid">PMC6269636</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ehf214713-cit-0023"><string-name name-style="western"><surname>Redfors</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Thorleifsson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jernberg</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Anger&#229;s</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Frobert</surname><given-names>O</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Short&#8208; and long&#8208;term clinical outcomes for patients with Takotsubo syndrome and patients with myocardial infarction: A report from the Swedish Coronary Angiography and Angioplasty Registry</article-title>. <source>J Am Heart Assoc</source><year>2021</year>;<volume>10</volume>:<elocation-id>e017290</elocation-id>. doi:<pub-id pub-id-type="doi">10.1161/JAHA.119.017290</pub-id><pub-id pub-id-type="pmid">34465127</pub-id><pub-id pub-id-type="pmcid">PMC8649294</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ehf214713-cit-0024"><string-name name-style="western"><surname>Santoro</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Ieva</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ferraretti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ienco</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Carpagnano</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lodispoto</surname><given-names>M</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Safety and feasibility of levosimendan administration in takotsubo cardiomyopathy: A case series</article-title>. <source>Cardiovasc Ther</source><year>2013</year>;<volume>31</volume>:<fpage>e133</fpage>&#8208;<lpage>e137</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1755-5922.12047</pub-id><pub-id pub-id-type="pmid">24119220</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ehf214713-cit-0025"><string-name name-style="western"><surname>Singh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Parsaik</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>B</given-names></string-name>. <article-title>Recurrent takotsubo cardiomyopathy: Variable pattern of ventricular involvement</article-title>. <source>Herz</source><year>2014</year>;<volume>39</volume>:<fpage>963</fpage>&#8208;<lpage>967</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00059-013-3896-x</pub-id><pub-id pub-id-type="pmid">23880950</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ehf214713-cit-0026"><string-name name-style="western"><surname>Templin</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ghadri</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Diekmann</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Napp</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Bataiosu</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Jaguszewski</surname><given-names>M</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Clinical features and outcomes of takotsubo (stress) cardiomyopathy</article-title>. <source>N Engl J Med</source><year>2015</year>;<volume>373</volume>:<fpage>929</fpage>&#8208;<lpage>938</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1406761</pub-id><pub-id pub-id-type="pmid">26332547</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ehf214713-cit-0027"><string-name name-style="western"><surname>Silverio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Parodi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Scudiero</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bossone</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>di Maio</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vriz</surname><given-names>O</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Beta&#8208;blockers are associated with better long&#8208;term survival in patients with Takotsubo syndrome</article-title>. <source>Heart</source><year>2022</year>;<volume>108</volume>:<fpage>1369</fpage>&#8208;<lpage>1376</lpage>. doi:<pub-id pub-id-type="doi">10.1136/heartjnl-2021-320543</pub-id><pub-id pub-id-type="pmid">35361673</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ehf214713-cit-0028"><string-name name-style="western"><surname>Meimoun</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>De Zuttere</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kasongo</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lardoux</surname><given-names>H</given-names></string-name>. <article-title>Dobutamine stress echocardiography&#8208;induced Takotsubo cardiomyopathy. Which triggers?</article-title><source>Eur Heart J</source><year>2021</year>;<volume>42</volume>:<elocation-id>1175</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehab724.1175</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ehf214713-cit-0029"><string-name name-style="western"><surname>Shao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Redfors</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Scharin T&#228;ng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>M&#246;llmann</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Troidl</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Szardien</surname><given-names>S</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Novel rat model reveals important roles of &#946;&#8208;adrenoreceptors in stress&#8208;induced cardiomyopathy</article-title>. <source>Int J Cardiol</source><year>2013</year>;<volume>168</volume>:<fpage>1943</fpage>&#8208;<lpage>1950</lpage>. (Article). doi:<pub-id pub-id-type="doi">10.1016/j.ijcard.2012.12.092</pub-id><pub-id pub-id-type="pmid">23357048</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="ehf214713-cit-0030"><string-name name-style="western"><surname>Jaguszewski</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Gasecka</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hering</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Filipiak</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Szarpak</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fija&#322;kowski</surname><given-names>M</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Levosimendan improves the acute course of takotsubo syndrome: A pooled analysis</article-title>. <source>ESC Heart Fail</source><year>2021</year>;<volume>8</volume>:<fpage>4360</fpage>&#8208;<lpage>4363</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ehf2.13486</pub-id><pub-id pub-id-type="pmid">34342162</pub-id><pub-id pub-id-type="pmcid">PMC8497347</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="ehf214713-cit-0031"><string-name name-style="western"><surname>De Backer</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Debonnaire</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gevaert</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Missault</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gheeraert</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Muyldermans</surname><given-names>L</given-names></string-name>. <article-title>Prevalence, associated factors and management implications of left ventricular outflow tract obstruction in takotsubo cardiomyopathy: A two&#8208;year, two&#8208;center experience</article-title>. <source>BMC Cardiovasc Disord</source><year>2014</year>;<volume>14</volume>:<elocation-id>147</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/1471-2261-14-147</pub-id><pub-id pub-id-type="pmid">25339604</pub-id><pub-id pub-id-type="pmcid">PMC4210484</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="ehf214713-cit-0032"><string-name name-style="western"><surname>Gersh</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Maron</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Bonow</surname><given-names>RO</given-names></string-name>, <string-name name-style="western"><surname>Dearani</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Fifer</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Link</surname><given-names>MS</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source>Circulation</source><year>2011</year>;<volume>124</volume>:<fpage>2761</fpage>&#8208;<lpage>2796</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIR.0b013e318223e230</pub-id><pub-id pub-id-type="pmid">22068435</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="ehf214713-cit-0033"><string-name name-style="western"><surname>Ali</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Redfors</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lundgren</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Alkhoury</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Oras</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>LM</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Effects of pretreatment with cardiostimulants and beta&#8208;blockers on isoprenaline&#8208;induced takotsubo&#8208;like cardiac dysfunction in rats</article-title>. <source>Int J Cardiol</source><year>2019</year>;<volume>281</volume>:<fpage>99</fpage>&#8208;<lpage>104</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijcard.2018.12.045</pub-id><pub-id pub-id-type="pmid">30638749</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="ehf214713-cit-0034"><string-name name-style="western"><surname>Felker</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>O'Connor</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Braunwald</surname><given-names>E</given-names></string-name>, 
<collab collab-type="authors">Heart Failure Clinical Research Network I</collab>
. <article-title>Loop diuretics in acute decompensated heart failure: Necessary? Evil? A necessary evil?</article-title><source>Circ Heart Fail</source><year>2009</year>;<volume>2</volume>:<fpage>56</fpage>&#8208;<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.108.821785</pub-id><pub-id pub-id-type="pmid">19750134</pub-id><pub-id pub-id-type="pmcid">PMC2742422</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="ehf214713-cit-0035"><string-name name-style="western"><surname>Sverrisdottir</surname><given-names>YB</given-names></string-name>, <string-name name-style="western"><surname>Schultz</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Omerovic</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Elam</surname><given-names>M</given-names></string-name>. <article-title>Sympathetic nerve activity in stress&#8208;induced cardiomyopathy</article-title>. <source>Clin Auton Res</source><year>2012</year>;<volume>22</volume>:<fpage>259</fpage>&#8208;<lpage>264</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10286-012-0162-x</pub-id><pub-id pub-id-type="pmid">22492095</pub-id><pub-id pub-id-type="pmcid">PMC3501184</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="ehf214713-cit-0036"><string-name name-style="western"><surname>Burnier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brunner</surname><given-names>HR</given-names></string-name>. <article-title>Neurohormonal consequences of diuretics in different cardiovascular syndromes</article-title>. <source>Eur Heart J</source><year>1992</year>;<volume>13</volume>:<fpage>28</fpage>&#8208;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/13.suppl_g.28</pub-id><pub-id pub-id-type="pmid">1362543</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="ehf214713-cit-0037"><string-name name-style="western"><surname>Rizzetto</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Widmann</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tavella</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zanolla</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pighi</surname><given-names>M</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Prognostic impact of antiplatelet therapy in Takotsubo syndrome: A systematic review and meta&#8208;analysis of the literature</article-title>. <source>Heart Fail Rev</source><year>2022</year>;<volume>27</volume>:<fpage>857</fpage>&#8208;<lpage>868</lpage>. (Review) (In English). doi:<pub-id pub-id-type="doi">10.1007/s10741-021-10099-5</pub-id><pub-id pub-id-type="pmid">33779884</pub-id><pub-id pub-id-type="pmcid">PMC9033728</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="ehf214713-cit-0038"><string-name name-style="western"><surname>Cecchi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Parodi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Giglioli</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Passantino</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bandinelli</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liotta</surname><given-names>AA</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Stress&#8208;induced hyperviscosity in the pathophysiology of takotsubo cardiomyopathy</article-title>. <source>Am J Cardiol</source><year>2013</year>;<volume>111</volume>:<fpage>1523</fpage>&#8208;<lpage>1529</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjcard.2013.01.304</pub-id><pub-id pub-id-type="pmid">23465096</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="ehf214713-cit-0039"><string-name name-style="western"><surname>Y&#8208;Hassan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Holmin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Abdula</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>B&#246;hm</surname><given-names>F</given-names></string-name>. <article-title>Thrombo&#8208;embolic complications in takotsubo syndrome: Review and demonstration of an illustrative case</article-title>. <source>Clin Cardiol</source><year>2019</year>;<volume>42</volume>:<fpage>312</fpage>&#8208;<lpage>319</lpage>. doi:<pub-id pub-id-type="doi">10.1002/clc.23137</pub-id><pub-id pub-id-type="pmid">30565272</pub-id><pub-id pub-id-type="pmcid">PMC6712329</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="ehf214713-cit-0040"><string-name name-style="western"><surname>Tai</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Effect of angiotensin&#8208;converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: A meta&#8208;analysis of randomized controlled trials</article-title>. <source>BMC Cardiovasc Disord</source><year>2017</year>;<volume>17</volume>:<fpage>257</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12872-017-0686-z</pub-id><pub-id pub-id-type="pmid">28982370</pub-id><pub-id pub-id-type="pmcid">PMC5629775</pub-id></mixed-citation></ref><ref id="ehf214713-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="ehf214713-cit-0041"><string-name name-style="western"><surname>Omerovic</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>James</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Erlinge</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hagstr&#246;m</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Venetsanos</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Henareh</surname><given-names>L</given-names></string-name>, <italic toggle="yes">et al</italic>. <article-title>Rationale and design of BROKEN&#8208;SWEDEHEART: A registry&#8208;based, randomized, parallel, open&#8208;label multicenter trial to test pharmacological treatments for broken heart (takotsubo) syndrome</article-title>. <source>Am Heart J</source><year>2023</year>;<volume>257</volume>:<fpage>33</fpage>&#8208;<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ahj.2022.11.010</pub-id><pub-id pub-id-type="pmid">36435233</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>